FCA
ZYME icon

FinTrust Capital Advisors’s Zymeworks ZYME Stock Holding History

FinTrust Capital Advisors’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-300
Closed -$14 – 1161
2020
Q3 		$14 Buy
+300
New +$10.3K ﹤0.01% 729

Other funds holding ZYME

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

FinTrust Capital Advisors's ZYME Position: Q4 2020 in Review

FinTrust Capital Advisors sold out of Zymeworks (ZYME) in Q4 2020, closing a stake of 300 shares — an estimated $14 sold.

FinTrust Capital Advisors first reported a position in ZYME in Q3 2020 and held it in 1 quarter. The position peaked at $14 in Q3 2020. 138 funds tracked by Wall St. Rank hold ZYME as of Q4 2020.

  • FinTrust Capital Advisors reported no remaining Zymeworks position as of Q4 2020 after selling out during the quarter.
  • FinTrust Capital Advisors sold 300 Zymeworks shares in Q4 2020, an estimated $14.
  • FinTrust Capital Advisors first reported a position in Zymeworks in Q3 2020 and held it in 1 quarter.
  • FinTrust Capital Advisors's Zymeworks position peaked at $14 in Q3 2020.
  • 138 funds tracked by Wall St. Rank held Zymeworks as of Q4 2020.

Based on FinTrust Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.